Actively Recruiting
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Led by University Hospital, Basel, Switzerland · Updated on 2025-12-23
350
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how the metabolism of cancer and immune cells affects the bone marrow environment, therapy resistance, and outcomes in blood cancers such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis. These cancers often require chemotherapy and stem cell transplants, but relapse remains common. Understanding metabolic interactions in the bone marrow could lead to new treatment strategies. The study observes participants with hematological cancers and healthy stem cell donors to analyze metabolic processes. It involves detailed profiling of metabolites, lipids, gene expression, and metabolic function at multiple points: at diagnosis, after chemotherapy, before stem cell transplant, and up to one year post-transplant, including at relapse if it occurs. This observational research aims to uncover critical metabolic pathways influencing disease progression and treatment response. Participants will undergo regular assessments including blood and bone marrow sampling for metabolic and molecular analysis. Researchers will track treatment responses, progression-free survival, and overall survival for up to five years after transplant. The study collects data at various timepoints to monitor how metabolism changes over the course of treatment and disease, aiming to improve understanding and guide personalized therapies in hematologic cancers.
CONDITIONS
Brief Title
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Signed written informed consent
- Diagnosis of MDS, AML, ALL, PMF, or post-ET/PV myelofibrosis for participants with hematological cancers
You will not qualify if you...
- Pregnant or lactating women
- Inability to give consent
- Active malignant disease other than MDS, AML, ALL, PMF, or post-ET/PV myelofibrosis within the last 3 years prior to study inclusion
- For healthy donors: previous or current hematological disease
- For healthy donors: previous or current other malignant disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 months
Participants undergo metabolic profiling and expression analysis at primary diagnosis and after initial chemotherapy to assess cancer and immune cell metabolism.
Visits at primary diagnosis and after initial chemotherapy
Duration - Up to 5 years
Participants are monitored with metabolic and expression profiling before allogeneic hematopoietic stem cell transplantation (allo-HSCT) and at multiple time points after transplantation to study metabolic changes and treatment outcomes.
Multiple visits before allo-HSCT and at 1, 3, 6, and 12 months, and up to 5 years after allo-HSCT
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
P
Petya Apostolova, Prof. Dr.
J
Johannes Tossounidis, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here